370 related articles for article (PubMed ID: 24959088)
1. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis.
Vyas D; Laput G; Vyas AK
Onco Targets Ther; 2014; 7():1015-23. PubMed ID: 24959088
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.
Lee KW; Kim JH; Yun T; Song EK; Na II; Shin H; Oh SY; Choi IS; Oh DY; Kim DW; Im SA; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S115-21. PubMed ID: 17923737
[TBL] [Abstract][Full Text] [Related]
3. Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?
Vyas D; Deshpande K; Chaturvedi L; Gieric L; Ching K
J Clin Med Res; 2016 Feb; 8(2):162-7. PubMed ID: 26767086
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
7. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
8. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
10. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Abbas A; Nehme E; Fakih M
Anticancer Res; 2011 Dec; 31(12):4637-40. PubMed ID: 22199342
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Int J Oncol; 2005 Jun; 26(6):1563-7. PubMed ID: 15870870
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
14. A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Wang Y; Wang ZQ; Jiang YX; Wang FH; Luo HY; Liang Y; Wang DS; Li YH
Expert Opin Pharmacother; 2016 Aug; 17(12):1585-90. PubMed ID: 27328125
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy of breast cancer.
Norton L
Semin Oncol; 1994 Aug; 21(4 Suppl 7):19-24. PubMed ID: 8091238
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell adaptation to chemotherapy.
Di Nicolantonio F; Mercer SJ; Knight LA; Gabriel FG; Whitehouse PA; Sharma S; Fernando A; Glaysher S; Di Palma S; Johnson P; Somers SS; Toh S; Higgins B; Lamont A; Gulliford T; Hurren J; Yiangou C; Cree IA
BMC Cancer; 2005 Jul; 5():78. PubMed ID: 16026610
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer.
Liu Y; Ren Z; Yuan L; Xu S; Yao Z; Qiao L; Li K
Am J Cancer Res; 2016; 6(10):2345-2350. PubMed ID: 27822423
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma.
Kosugi S; Kanda T; Nakagawa S; Ohashi M; Nishimaki T; Hatakeyama K
Scand J Gastroenterol; 2005 Aug; 40(8):886-92. PubMed ID: 16170897
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy.
Koukourakis IM; Zygogianni A; Kouloulias V; Koukourakis MI
Chemotherapy; 2021; 66(3):82-86. PubMed ID: 34233328
[TBL] [Abstract][Full Text] [Related]
20. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
